Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Heidelberg University
Headquarters: Heidelberg, Germany
Website: http://www.uni-heidelberg.de...
Year Founded: 1386
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Feb 29, 2024
Discovery & Translation
Science spotlight: SOX9 switch for kidney regeneration, improved base editors and more
BioCentury’s roundup of translational innovations
BioCentury | Sep 23, 2022
Discovery & Translation
Neonatal disease interception for Huntington disease; two self-assembling vaccines and more
BioCentury’s roundup of translational news
BioCentury | Feb 11, 2022
Distillery Therapeutics
Targeting endothelial YAP/TAZ to reduce tumor angiogenesis
BioCentury | Apr 17, 2021
Deals
As German translational science begins to bloom, Evotec, BMS launch incubator in Rhine-Main-Neckar region
Evotec’s latest ‘BRIDGE’ incubator comes with $20M to accelerate academic research
BioCentury | Feb 26, 2021
Deals
Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology
Led by Sean Nolan as executive chairman and Joe Nolan as CEO, the former management team of AveXis partnered with Deerfield Management to launch Jaguar Gene Therapy LLC. Jaguar’s preclinical
BioCentury | Jan 1, 2021
Targets & Mechanisms
A snapshot of target innovation in 2020
An analysis of BioCentury’s Distillery captures trends from preclinical publications in 2020
BioCentury | Oct 31, 2020
Translation in Brief
A method to collect tumor-specific T cells; plus research from Heidelberg University, Black Diamond, KSQ and SynDevRx
BioCentury’s roundup of translational news
BioCentury | Oct 28, 2020
Distillery Therapeutics
Targeting the NMDA receptor-TRPM4 complex for neurodegeneration
DISEASE CATEGORY: Neurology
INDICATION: Stroke; neurology Disruption of the NMDA receptor-TRPM4 complex could treat ischemic stroke and other neurodegenerative diseases with NMDA receptor
INDICATION: Stroke; neurology Disruption of the NMDA receptor-TRPM4 complex could treat ischemic stroke and other neurodegenerative diseases with NMDA receptor
BioCentury | Apr 4, 2020
Translation in Brief
HiFiBiO’s platform for antibody screening applied to COVID-19; plus Fundamental’s peptide mimetics for stroke, and BMS-IONpath
BioCentury's roundup of preclinical news
BioCentury | Sep 20, 2019
Emerging Company Profile
Divide & Conquer: short-circuiting tumor lines of communication
Divide & Conquer aims to prevent cancer cells from sharing resistance mechanisms via multicellular networks
Items per page:
1 - 10 of 50